Home › Funds › Royce & Associates › CYTK
Royce & Associates position in CYTK
CYTOKINETICS INC · Health Care
Latest position (Q2 2026)101.62K sh
Reported value held$8.66M
Portfolio Weight0.07%
First reportedQ1 2024
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 14.25K | $999.07K | New |
| Q2 2024 | 14.25K | $772.07K | Hold |
| Q3 2024 | 24.25K | $1.28M | Add |
| Q3 2025 | 100.08K | $5.50M | New |
| Q4 2025 | 144.43K | $9.18M | Add |
| Q1 2026 | 124.30K | $8.19M | Reduce |
| Q2 2026 | 101.62K | $8.66M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding CYTK
- BlackRock Inc 20.09M sh · $1.71B · Q2 2026
- Vanguard Group 12.05M sh · $765.54M · Q4 2025
- Geode Capital Management 3.71M sh · $316.33M · Q2 2026
- Citadel Advisors 1.97M sh · $167.55M · Q2 2026
- Capital Research Global Investors 1.69M sh · $143.68M · Q2 2026
- Northern Trust Corp 1.65M sh · $140.34M · Q2 2026
- Point72 Asset Management 1.59M sh · $135.31M · Q2 2026
- Charles Schwab Investment Management 1.57M sh · $133.39M · Q2 2026
- Principal Global Investors 1.31M sh · $111.74M · Q2 2026
- Invesco Ltd 1.24M sh · $105.24M · Q2 2026
- UBS Group AG 1.17M sh · $99.78M · Q2 2026
- D. E. Shaw & Co 1.05M sh · $89.29M · Q2 2026